African innovators are increasingly turning research into market-ready technologies

New research from the World Intellectual Property Organization highlights the importance of connecting research, finance and industry to help African innovations reach customers.

The Global Innovation Index (GII) 2026 examines how science-based startups and university spinouts turn frontier research into commercial ventures, identifying opportunities alongside gaps in funding, infrastructure and market access.

The report identifies more than 30,000 deep-science startups created globally since 2000, with a combined value of US$7.6 trillion.

They attracted US$122 billion in venture capital in 2025, underlining the commercial potential of scientific research.

Africa’s position remains limited. WIPO identified 25 deep-science startups and spinouts in South Africa, while its analysis of patent-holding deep-science startups identified only five across sub-Saharan Africa: four in South Africa and one in Kenya. However, the broader regional count of deep-science startups grew 65% between 2020 and 2025.

Scientific research does not automatically produce marketable products. Innovators must demonstrate that technologies work, meet regulatory requirements, attract investment and respond to market demand.

“There is often a desire to be the person who invents something for the first time or introduces a shiny new innovation, even when that innovation has not been adequately tested, validated or adapted to its intended context,” said Sarah Owusu, co-founder of Inkdot, an innovation consultancy based in Mozambique.

Owusu, who also co-founded the African leadership storytelling platform We Will Lead Africa, argues that innovation efforts should focus on improving existing solutions.

“We would be better served by examining what already works, improving it, scaling it or transferring it to other countries and communities rather than constantly trying to invent something new,” she told bird story agency.

South Africa’s University of Cape Town (UCT) illustrates how institutional infrastructure can help research reach the market.

In May 2026, UCT’s Biomedical Engineering Research Centre (BMERC) secured a medical-device manufacturing licence from the South African Health Products Regulatory Authority (SAHPRA), authorising it to manufacture, distribute and wholesale eligible registered devices.

BMERC director Professor Sudesh Sivarasu said the centre had spent more than a decade building a medical-technology pipeline that includes 23 patent families, five spinout companies and more than 100,000 devices distributed globally. Yet it had lacked a certified manufacturing pathway for clinical use in South Africa.

“The problem we set out to solve wasn’t simply technical; it was structural,” Sivarasu said in a statement issued by UCT.

“In the medical device sector, quality is synonymous with patient safety,” he said, explaining that the licence provides the regulatory foundation for manufacturing and distributing eligible devices.

The development could reduce dependence on imported technologies designed for healthcare systems with different resources and clinical needs. BMERC aims to have devices manufactured at UCT’s medical school in routine use in South African public hospitals within 18 to 24 months of the May announcement.

Ghana-based Yemaachi Biotech offers another example of research moving towards commercial application.

Its African Cancer Atlas, a clinical and genomic research platform spanning Ghana, Nigeria, Côte d’Ivoire, Kenya and Seychelles, had recruited 236 participants by May 2026 to support breast cancer research across African populations.

In June, OneBio Venture Studio announced a second investment in Yemaachi, which is building a cancer database to support diagnostic tools and next-generation cancer drugs.

The research has identified differences in triple-negative breast cancer among participants across the five countries, although further work is needed to translate the findings into clinical applications.

Kenya’s Octavia Carbon illustrates the commercial potential of science-based businesses developing technologies for emerging markets.

The Nairobi-headquartered company operates a direct-air-capture (DAC) manufacturing facility and is expanding deployment in Kenya’s Great Rift Valley.

Its Project Hummingbird facility is designed to remove up to 1,000 tonnes of carbon dioxide annually at full capacity, with the captured gas intended for permanent geological storage in basalt formations, where it can mineralise over time.

WIPO identifies Octavia Carbon among the region’s patent-holding deep-science startups, recording two patent families in its 2010–2025 dataset. Patents can protect intellectual property, but commercial viability ultimately depends on reliable operations, customers and the ability to expand at a sustainable cost.

Across healthcare, agriculture and energy, the challenge is connecting scientific advances to markets that can sustain them.

For Owusu, a major constraint is fragmented funding across the innovation value chain. Research grants may finance initial ideas, but entrepreneurs need additional resources to develop prototypes, demonstrate performance and meet regulatory requirements. Commercial investors, meanwhile, often want evidence that a technology works and has a viable market.

“For innovation to take root across Africa, different types of capital and funding must come together along the innovation value chain,” Owusu said.

Grants and philanthropic funding can support early-stage research when outcomes remain uncertain, while other forms of capital can finance growth once a solution has demonstrated its potential.

“The gap is that these different actors are not working together coherently enough,” she said. “We need a stronger ecosystem approach, with clear handovers between the different players.”

A July 2026 policy brief by the African Center for Economic Transformation (ACET), drawing on assessments in Ghana and Nigeria, identified similar weaknesses in research commercialisation. It called for better coordination between universities, businesses, financiers and government, alongside financing mechanisms and public procurement policies that help innovations reach markets.

WIPO similarly identifies proof-of-concept financing, testing facilities, patient capital and early customers as important to commercial deployment. Government procurement could help new technologies demonstrate their value in real operating environments.

Public hospitals, for example, could become customers for medical devices once they meet applicable safety and regulatory requirements.

The Masakhane Research Foundation offers another example of research addressing African market needs. It develops African-language datasets and natural-language-processing research to support artificial intelligence applications, addressing the limited digital representation of many African languages.

These resources can support language technologies for education, healthcare and public services, although further work is needed to develop applications, test them with users and establish sustainable distribution models.

Owusu argues that communities must participate in research rather than simply supply knowledge that others later commercialise.

“Communities should be recognised as participants in the research process, rather than simply having their knowledge extracted and then seeing others profit from it,” she said.

This matters in healthcare, agriculture and energy, where local conditions determine whether technologies are affordable, practical and effective. Opportunities lie not only in developing new products, but also in adapting existing solutions and extending their reach to underserved communities.

The GII 2026 ranks Mauritius 50th among 139 economies, South Africa 63rd, Botswana 82nd, Senegal 90th, Rwanda 96th and Kenya 97th. The rankings assess innovation performance across multiple indicators rather than directly measuring research commercialisation.